Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Panel Discussion on the COVID Vaccine

3.370 Aufrufe

Veröffentlicht am

Panel Discussion on the COVID Vaccine:
Operational and Clinical Preparedness
as presented at the Weitzman ECHO
on October 21, 2020

Veröffentlicht in: Gesundheitswesen
  • Als Erste(r) kommentieren

Panel Discussion on the COVID Vaccine

  1. 1. Panel Discussion on the COVID Vaccine: Operational and Clinical Preparedness October 21, 2020
  2. 2. CME Credit • Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians. The Bridgeport Hospital Yale New Haven Health designates this live activity for a maximum of one (1) AMA PRA Category 1 CreditsTM. Physicians should claim only credits commensurate with the extent of their participation in the various activities. • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Bridgeport Hospital Yale New Haven Health and the Weitzman Institute. Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State Medical Society to provide continuing medical education for physicians. • The content of this activity is not related to products or services of an ACCME- defined commercial interest; therefore, no one in control of content has a relevant financial relationship to disclose and there is no potential for conflicts of interest.
  3. 3. www.criver.com Panel Discussion on the COVID Vaccine: Operational and Clinical Preparedness
  4. 4. COVID-19 in the United States 8,272,427 cases on 10/21/20 up from 7,856,321 cases on 10/13/20 220,992 deaths https://coronavirus.jhu.edu/map.html
  5. 5. Increasing
  6. 6. Viral Transmission - Updates • ‘Expect numbers to continue to increase’ – Dr. Hoetz • Main transmission: coughs, droplets >> surfaces – Air-conditioning? • Dr. Nardell - Hot weather -> seek air conditioning -> not socially distancing; rebreathing the air that people have just exhaled – Sewage – Virus can be found in feces • Not Polio! No infections documented (CDC)
  7. 7. Co-infections? (SARS-CoV-2 + ???) • Rare to have co-infections • 3% viral coinfection • RSV, Influenza A • (less than flu!) • GET A FLU SHOT! Co-infections in people with COVID-19: a systematic review and meta-analysis Lansbury L, Lim B, Baskaran V, Lim WS. J Infect. 2020 Aug; 81(2): 266–275.
  8. 8. Virus • SARS-CoV-2 has a ‘proofreading’ enzyme – Corrects potentially fatal copying mistakes – Mutates 2 to 6x SLOWER than influenza • What is known about mutations so far? – 6 major strains (L– original strain, S -first new strain, V, G/GR/GH- most widespread) • GH most widespread in USA https://www.sciencedaily.com/releases/2020/08/200803105246.htm
  9. 9. Vaccines • Different technologies (Sept 30th ECHO) • One shot/two shots – Viral mutations – more shots required? Multivalent vaccine? • Safety – Those with underlying disease
  10. 10. COVID-19 Vaccine Overview * https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines # https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate- vaccines • 169 COVID-19 vaccine candidates under development*, # – 44 of these in human trials – 10 are in Phase 3 • Different platforms: – Inactivated, non-replicating viral vector, protein subunit, RNA, DNA, VLP, replicating viral vector…
  11. 11. What are the lead vaccine candidate(s) • Pfizer mRNA • Moderna mRNA • J&J – Recombinant, replication-incompetent adenovirus type 26 (Ad26) vector, constructed to encode (SARS-CoV-2) spike (S) protein • Astra Zeneca/University of Oxford – Modified chimp adenovirus vector (ChAdOx1
  12. 12. Dr. Scholand’s best guess • mRNA vaccine, BNT162b2 – Lipid nanoparticles mRNA encoding spike glycoprotein (S) • The target of virus neutralizing antibodies • 43,000 participants; including children aged 12 • 2 doses: mild to moderate side effects – Minus 80 Celcius (112 Fahrenheit) • Pfizer CEO: Results by ‘end of November’ • Emergency Use Authorization: + 2 months
  13. 13. Dr. Fauci • In the news again – He is right, we should listen to him! • Wear a mask • Social distance • Wash hands • Avoid large groups • Still try to do things OUTSIDE, rather than IN
  14. 14. Resources • Nuvance health 1400+ articles reviewed: https://spark.adobe.com/page/fwhfDctGtttlw/ • CDC: https://www.cdc.gov/coronavirus/2019-ncov/index.html https://emergency.cdc.gov/coca/calls/2020/ • WHO: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 • Johns Hopkins: https://coronavirus.jhu.edu/map.html • Others https://www.thelancet.com/coronavirus https://covidactnow.org/
  15. 15. REMINDER Next Session is November 4th Future Sessions: 1st and 3rd Wednesdays
  16. 16. Thank You! To learn more about The Path Forward series WeitzmanLearning.org/the-path-forward To view previous COVID-19 sessions: WeitzmanLearning.org/coronavirus